Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday. The biotech sector has seen a notable comeback as fresh capital flows back into the industry, improving market sentiment after a prolonged downturn.
Founded in 2017, Apnimed is a clinical-stage company focused on developing oral medicines to treat obstructive sleep apnea (OSA) and related disorders. The company’s lead drug candidate, AD109, an experimental once-daily pill for obstructive sleep apnea, in May met the primary endpoint in a late-stage trial, potentially offering a convenient alternative to device-based treatments.
Apnimed has submitted a marketing application for AD109 and expects a potential FDA decision date in the first quarter of 2027. BofA Securities, Evercore ISI, Cantor, and LifeSci Capital are the underwriters for the offering. The company intends to list its shares on Nasdaq under the symbol “APMD.”
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
